

Lipika Goyal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7074516/publications.pdf>

Version: 2024-02-01

131
papers

7,793
citations

87843

38
h-index

56687

83
g-index

135
all docs

135
docs citations

135
times ranked

8905
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR Aberrations: A Phase I Dose-Expansion Study. <i>Cancer Discovery</i> , 2022, 12, 402-415. | 7.7 | 119 |
| 2 | Mutant IDH Inhibits IFN-3 TET2 Signaling to Promote Immune Evasion and Tumor Maintenance in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 812-835. | 7.7 | 55 |
| 3 | A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS485-TPS485. | 0.8 | 1 |
| 4 | Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. <i>Cancer Discovery</i> , 2022, 12, 1462-1481. | 7.7 | 30 |
| 5 | EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 1378-1395. | 7.7 | 33 |
| 6 | PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4171-TPS4171. | 0.8 | 6 |
| 7 | Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR fusions/rearrangements.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4009-4009. | 0.8 | 33 |
| 8 | Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6570-6570. | 0.8 | 0 |
| 9 | Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9601-TPS9601. | 0.8 | 0 |
| 10 | Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627. | 2.0 | 7 |
| 11 | The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. <i>Oncologist</i> , 2021, 26, e1036-e1049. | 1.9 | 30 |
| 12 | Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS351-TPS351. | 0.8 | 3 |
| 13 | Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132. | 1.5 | 30 |
| 14 | A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS358-TPS358. | 0.8 | 3 |
| 15 | Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1054-1064. | 13.9 | 2 |
| 16 | FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 2488-2505. | 7.7 | 46 |
| 17 | Targeting FGFR inhibition in cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2021, 95, 102170. | 3.4 | 85 |
| 18 | First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4165-TPS4165. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. <i>Nature Communications</i> , 2021, 12, 3199. | 5.8 | 33 |
| 20 | Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6560-6560. | 0.8 | 0 |
| 21 | Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16253-e16253. | 0.8 | 0 |
| 22 | Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab. <i>Kidney International Reports</i> , 2021, 6, 1464-1468. | 0.4 | 9 |
| 23 | FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with <i>FGFR2</i> fusions/rearrangements.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4097-4097. | 0.8 | 4 |
| 24 | Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15611-e15611. | 0.8 | 1 |
| 25 | Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4164-TPS4164. | 0.8 | 1 |
| 26 | Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant- <i>IDH1</i> cholangiocarcinoma. <i>Future Oncology</i> , 2021, 17, 2057-2074. | 1.1 | 14 |
| 27 | Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with <i>FGFR2</i> fusions/rearrangements. <i>Cancer Research</i> , 2021, 81, CT010-CT010. | 0.4 | 28 |
| 28 | Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021, 21, 1119-1126. | 0.5 | 13 |
| 29 | P024â€¦KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. , 2021, , . | | 1 |
| 30 | Paving a pathway for drug development in HER2-positive biliary tract cancer. <i>Lancet Oncology</i> , The, 2021, 22, 1204-1206. | 5.1 | 0 |
| 31 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794. | | 43 |
| 32 | Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669. | 3.4 | 194 |
| 33 | Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with <i>FGFR2</i> fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815. | 3.7 | 205 |
| 34 | Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival in patients with metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 154-154. | 0.8 | 0 |
| 35 | Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.. <i>Journal of Clinical Oncology</i> , 2021, 39, 265-265. | 0.8 | 70 |
| 36 | Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 541-565. | 2.3 | 477 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Combining systemic and local therapies for hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 976-978. | 3.7 | 2 |
| 38 | Integration of Systemic and Liver-Directed Therapies for Locally Advanced Hepatocellular Cancer: Harnessing Potential Synergy for New Therapeutic Horizons. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 567-576. | 2.3 | 4 |
| 39 | Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135. | 5.7 | 112 |
| 40 | Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 3.9 | 56 |
| 41 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 433-444. | 1.2 | 69 |
| 42 | Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. <i>Journal of Clinical Pathology</i> , 2020, 73, 23-29. | 1.0 | 14 |
| 43 | Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1871-1884. | 3.3 | 32 |
| 44 | Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. <i>Practical Radiation Oncology</i> , 2020, 10, e183-e187. | 1.1 | 2 |
| 45 | A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. <i>Investigational New Drugs</i> , 2020, 38, 1533-1539. | 1.2 | 13 |
| 46 | Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 1122-1129. | 0.7 | 29 |
| 47 | Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435. | | 87 |
| 48 | Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172. | 0.7 | 4 |
| 49 | Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6158-6167. | 3.2 | 37 |
| 50 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClariDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807. | 5.1 | 620 |
| 51 | Randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers. <i>Cancer</i> , 2020, 126, 3569-3578. | 2.0 | 6 |
| 52 | Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. <i>Chinese Clinical Oncology</i> , 2020, 9, 7-7. | 0.4 | 4 |
| 53 | Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384. | 1.1 | 62 |
| 54 | Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885. | 3.2 | 67 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 161-173. | 1.8 | 7 |
| 56 | FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring <i>FGFR2</i> gene fusions or other rearrangements.. Journal of Clinical Oncology, 2020, 38, 108-108. | 0.8 | 61 |
| 57 | Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.. Journal of Clinical Oncology, 2020, 38, 3603-3603. | 0.8 | 23 |
| 58 | A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.. Journal of Clinical Oncology, 2020, 38, 4591-4591. | 0.8 | 5 |
| 59 | A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy.. Journal of Clinical Oncology, 2020, 38, 547-547. | 0.8 | 10 |
| 60 | Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology, 2020, 38, 567-567. | 0.8 | 1 |
| 61 | Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.. Journal of Clinical Oncology, 2020, 38, 693-693. | 0.8 | 4 |
| 62 | NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology, 2020, 16, 1069-1081. | 1.1 | 15 |
| 63 | The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2020, 38, 833-833. | 0.8 | 0 |
| 64 | NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. Journal of Clinical Oncology, 2020, 38, TPS602-TPS602. | 0.8 | 2 |
| 65 | Comparing clinicopathologic feature and treatment outcome of patients who underwent surgical resection or liver transplant for nonalcoholic fatty liver disease (NAFLD)-related and non-NAFLD related hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, e16675-e16675. | 0.8 | 0 |
| 66 | A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.. Journal of Clinical Oncology, 2020, 38, e16643-e16643. | 0.8 | 3 |
| 67 | Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma.. Journal of Clinical Oncology, 2020, 38, 580-580. | 0.8 | 0 |
| 68 | Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2020, 38, 149-149. | 0.8 | 2 |
| 69 | Clinical and genomic factors associated with outcome following ablative radiotherapy for oligometastatic and oligoprogressive liver tumors.. Journal of Clinical Oncology, 2020, 38, 515-515. | 0.8 | 3 |
| 70 | Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions.. Journal of Clinical Oncology, 2020, 38, 579-579. | 0.8 | 1 |
| 71 | Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer.. Journal of Clinical Oncology, 2020, 38, 186-186. | 0.8 | 0 |
| 72 | Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology and Hepatology, 2019, 4, 711-720. | 3.7 | 161 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 73 | Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421. | 15.2 | 359 |
| 74 | Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020. | 3.4 | 353 |
| 75 | Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China. <i>JAMA Oncology</i> , 2019, 5, 938. | 3.4 | 2 |
| 76 | Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 248-260. | 1.8 | 8 |
| 77 | TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079. | 7.7 | 254 |
| 78 | Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 64-72. | 0.4 | 99 |
| 79 | FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. <i>Cancer</i> , 2019, 125, 2213-2221. | 2.0 | 14 |
| 80 | Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 564-572. | 0.6 | 0 |
| 81 | A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 80-89. | 3.2 | 62 |
| 82 | The Tipping Point: Key Oncologic Imaging Findings Resulting in Critical Changes in the Management of Malignant Tumors of the Gastrointestinal Tract. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 61-74. | 0.6 | 2 |
| 83 | Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4084-4084. | 0.8 | 5 |
| 84 | Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4087-4087. | 0.8 | 42 |
| 85 | FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3157-TPS3157. | 0.8 | 18 |
| 86 | Changes in alpha-fetoprotein (AFP) and systemic therapy outcomes in advanced hepatocellular carcinoma (HCC): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 346-346. | 0.8 | 1 |
| 87 | Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 412-412. | 0.8 | 1 |
| 88 | Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 562-562. | 0.8 | 2 |
| 89 | FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS468-TPS468. | 0.8 | 6 |
| 90 | Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. <i>Journal of Clinical Oncology</i> , 2019, 37, 392-392. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 91 | Frequency and feasibility of detecting FGFR mRNA expression in archival samples of patients with cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2019, 37, 281-281. | 0.8 | 0 |
| 92 | Patterns of care and outcomes of definitive external beam radiotherapy and radioembolization for localized hepatocellular carcinoma: A propensity score-adjusted analysis.. Journal of Clinical Oncology, 2019, 37, 329-329. | 0.8 | 0 |
| 93 | External beam radiotherapy for hepatocellular carcinoma with right atrium tumor thrombus.. Journal of Clinical Oncology, 2019, 37, 328-328. | 0.8 | 1 |
| 94 | Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2019, 37, 3563-3563. | 0.8 | 2 |
| 95 | Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma. JAMA Oncology, 2018, 4, 963. | 3.4 | 426 |
| 96 | Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of Clinical Oncology, 2018, 36, 276-282. | 0.8 | 524 |
| 97 | Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942. | 1.3 | 21 |
| 98 | Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2018, 41, 1799-1802. | 0.9 | 45 |
| 99 | Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Practical Radiation Oncology, 2018, 8, 414-421. | 1.1 | 17 |
| 100 | Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. Journal of Clinical Oncology, 2018, 36, 4116-4116. | 0.8 | 9 |
| 101 | Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors.. Journal of Clinical Oncology, 2018, 36, e15674-e15674. | 0.8 | 7 |
| 102 | Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology, 2018, 36, 272-272. | 0.8 | 7 |
| 103 | Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for local advanced gastric or Siewert II/III GEJ cancer: A retrospective analysis.. Journal of Clinical Oncology, 2018, 36, 115-115. | 0.8 | 0 |
| 104 | An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1123-1128. | 3.3 | 133 |
| 105 | A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer, 2017, 123, 1979-1988. | 2.0 | 92 |
| 106 | Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. Journal of the National Cancer Institute, 2017, 109, . | 3.0 | 82 |
| 107 | Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discovery, 2017, 7, 252-263. | 7.7 | 384 |
| 108 | New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discovery, 2017, 7, 943-962. | 7.7 | 419 |

| # | ARTICLE | IF | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 109 | FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 368-368. | 0.8 | 1 |
| 110 | TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. Journal of Clinical Oncology, 2017, 35, 386-386. | 0.8 | 13 |
| 111 | Bridging the Gap Between Sorafenib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist, 2016, 21, 1283-1285. | 1.9 | 0 |
| 112 | Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2016, 6, 727-739. | 7.7 | 126 |
| 113 | Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 953-959. | 0.9 | 12 |
| 114 | The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Annals of Surgical Oncology, 2016, 23, 290-296. | 0.7 | 80 |
| 115 | Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 2016, 34, 460-468. | 0.8 | 363 |
| 116 | PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2016, 22, 470-478. | 3.2 | 168 |
| 117 | Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer.. Journal of Clinical Oncology, 2016, 34, e15603-e15603. | 0.8 | 6 |
| 118 | Gemcitabine (G) + nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.. Journal of Clinical Oncology, 2016, 34, 348-348. | 0.8 | 3 |
| 119 | A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Investigational New Drugs, 2015, 33, 128-137. | 1.2 | 40 |
| 120 | Chemotherapy and antiangiogenics in biliary tract cancer. Lancet Oncology, The, 2015, 16, 882-883. | 5.1 | 2 |
| 121 | Safety and Efficacy of 70â€“150 Î¼m and 100â€“300 Î¼m Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2015, 26, 516-522. | 0.2 | 62 |
| 122 | Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist, 2015, 20, 1019-1027. | 1.9 | 112 |
| 123 | A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma.. Journal of Clinical Oncology, 2015, 33, 800-800. | 0.8 | 9 |
| 124 | A comparative study of circulating biomarkers of anti-VEGF therapy in phase II trials in advanced hepatocellular carcinoma (HCC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 2543-2543. | 0.8 | 1 |
| 125 | Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 4128-4128. | 0.8 | 3 |
| 126 | Mismatch repair protein loss and microsatellite instability in cholangiocarcinoma.. Journal of Clinical Oncology, 2014, 32, 237-237. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 127 | Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is).. Journal of Clinical Oncology, 2014, 32, 9639-9639. | 0.8 | 0 |
| 128 | A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2014, 32, TPS4157-TPS4157. | 0.8 | 0 |
| 129 | Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 2310-2318. | 3.2 | 276 |
| 130 | A phase I study ofÂDENSPM (N1, N11-diethylnorspermine) in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 260-260. | 0.8 | 0 |
| 131 | A phase I study of ganetespib in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 259-259. | 0.8 | 1 |